Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kurt Huber

Showing results (581-590 of 642) with videos related to

Pageof 65
Sort By:
European Heart Journal. Cardiovascular Pharmacotherapy|October 17, 2024
Impact of ticagrelor with or without aspirin on total and recurrent bleeding and ischaemic events after percutaneous coronary intervention: a sub-study of the TWILIGHT trialUsman Baber, Davide Cao, Timothy Collier, et al.
BMJ Open|March 11, 2019
Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY)Sergio Leonardi, Anna Franzone, Raffaele Piccolo, et al.
European Heart Journal|October 18, 2021
Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBRJavier Escaned, Davide Cao, Usman Baber, et al.
Journal of the American College of Cardiology|November 2, 2019
Ticagrelor Alone Versus Dual Antiplatelet Therapy From 1 Month After Drug-Eluting Coronary StentingAnna Franzone, Eugène McFadden, Sergio Leonardi, et al.
International Journal of Cardiology|April 20, 2023
Biolimus-eluting vs. other limus-eluting stents in NSTE-ACS: A pooled analysis of GLASSY and TWILIGHTAlessandro Spirito, Marco Valgimigli, Davide Cao, et al.
JACC. Cardiovascular Interventions|July 9, 2021
Impact of Age on the Safety and Efficacy of Ticagrelor Monotherapy in Patients Undergoing PCIDominick J Angiolillo, Davide Cao, Usman Baber, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|May 16, 2025
Ticagrelor monotherapy versus ticagrelor plus aspirin in patients with chronic coronary syndrome and high ischaemic risk: a post hoc analysis of the TWILIGHT trialMauro Gitto, Usman Baber, Samantha Sartori, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|December 13, 2019
Impact of recruitment and retention on all-cause mortality in a large all-comers randomised controlled trial: insights from the GLOBAL LEADERS trialKuniaki Takahashi, Norihiro Kogame, Mariusz Tomaniak, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|September 17, 2020
PRECISE-DAPT score for bleeding risk prediction in patients on dual or single antiplatelet regimens: insights from the GLOBAL LEADERS and GLASSYFelice Gragnano, Dik Heg, Anna Franzone, et al.
Thrombosis and Haemostasis|September 23, 2016
A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI. Rationale and design of the Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes (TROPICAL-ACS) TrialDirk Sibbing, Dániel Aradi, Claudius Jacobshagen, et al.
Pageof 65

Showing results (581-590 of 642) with videos related to

Sort By:
Pageof 65
European Heart Journal. Cardiovascular Pharmacotherapy|October 17, 2024
Impact of ticagrelor with or without aspirin on total and recurrent bleeding and ischaemic events after percutaneous coronary intervention: a sub-study of the TWILIGHT trialUsman Baber, Davide Cao, Timothy Collier, et al.
BMJ Open|March 11, 2019
Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY)Sergio Leonardi, Anna Franzone, Raffaele Piccolo, et al.
European Heart Journal|October 18, 2021
Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBRJavier Escaned, Davide Cao, Usman Baber, et al.
Journal of the American College of Cardiology|November 2, 2019
Ticagrelor Alone Versus Dual Antiplatelet Therapy From 1 Month After Drug-Eluting Coronary StentingAnna Franzone, Eugène McFadden, Sergio Leonardi, et al.
International Journal of Cardiology|April 20, 2023
Biolimus-eluting vs. other limus-eluting stents in NSTE-ACS: A pooled analysis of GLASSY and TWILIGHTAlessandro Spirito, Marco Valgimigli, Davide Cao, et al.
JACC. Cardiovascular Interventions|July 9, 2021
Impact of Age on the Safety and Efficacy of Ticagrelor Monotherapy in Patients Undergoing PCIDominick J Angiolillo, Davide Cao, Usman Baber, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|May 16, 2025
Ticagrelor monotherapy versus ticagrelor plus aspirin in patients with chronic coronary syndrome and high ischaemic risk: a post hoc analysis of the TWILIGHT trialMauro Gitto, Usman Baber, Samantha Sartori, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|December 13, 2019
Impact of recruitment and retention on all-cause mortality in a large all-comers randomised controlled trial: insights from the GLOBAL LEADERS trialKuniaki Takahashi, Norihiro Kogame, Mariusz Tomaniak, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|September 17, 2020
PRECISE-DAPT score for bleeding risk prediction in patients on dual or single antiplatelet regimens: insights from the GLOBAL LEADERS and GLASSYFelice Gragnano, Dik Heg, Anna Franzone, et al.
Thrombosis and Haemostasis|September 23, 2016
A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI. Rationale and design of the Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes (TROPICAL-ACS) TrialDirk Sibbing, Dániel Aradi, Claudius Jacobshagen, et al.
Pageof 65